464:
25:
525:
83:
374:
Kim, Mi-Kyung; Lee, Dae Young; Jeong, Jiyoon; Grimm, Michael; Franey, Bridgette B.; Hompesch, Marcus (1 June 2021). "766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and
Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers
590:
208:
341:
Kim, Mi-Kyung; Cheong, Ye Hwang; Lee, Seung Ho; Kim, Tae Hyoung; Jung, Il Hoon; Chae, Yuna; Lee, Jeong-Ha; Yang, Eun Kyoung; Park, Hansu; Yang, Jae-Sung; Hong, Ki Whan (December 2021).
566:
509:
635:
222:
630:
250:
InChI=1S/C25H31F2N5O2/c1-4-17-14-28-25(29-15-17)32-9-7-18(8-10-32)6-5-11-33-19-12-20(26)22(21(27)13-19)23-30-24(16(2)3)34-31-23/h12-16,18H,4-11H2,1-3H3
559:
300:
Lee, Seung-Ho; Park, Hansu; Yang, Eun-Kyoung; Lee, Bo Ram; Jung, Il-Hoon; Kim, Tae-Hyoung; Goo, Moon Jung; Chae, Yuna; Kim, Mi-Kyung (October 2023).
502:
412:"DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice"
595:
552:
495:
242:
98:
343:"A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression"
302:"GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling"
276:
625:
410:
Kim, Youjin; Lee, Si Woo; Wang, Hyejin; Kim, Ryeong-Hyeon; Park, Hyun Ki; Lee, Hangkyu; Kang, Eun Seok (31 March 2022).
585:
475:
610:
615:
620:
605:
600:
471:
392:
443:
323:
433:
423:
384:
354:
313:
272:
145:
35:
532:
280:
536:
479:
438:
411:
129:
579:
396:
463:
359:
342:
318:
301:
184:
54:
44:
447:
327:
24:
428:
74:
388:
115:
524:
269:
82:
591:
Experimental drugs developed for non-alcoholic fatty liver disease
207:
198:
230:
CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(=N3)C(C)C)C(F)=C2)CC1
18:
106:
3-propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole
540:
483:
49:
39:
275:
developed by the South Korean company Dong-A ST for
196:
183:
144:
139:
114:
89:
128:
560:
503:
8:
73:
567:
553:
510:
496:
81:
437:
427:
358:
317:
292:
247:
227:
103:
72:
7:
521:
519:
460:
458:
636:Systemic hormonal preparation stubs
119:
631:Gastrointestinal system drug stubs
14:
416:Diabetes & Metabolism Journal
347:Biomedicine & Pharmacotherapy
306:Biomedicine & Pharmacotherapy
523:
462:
168:
162:
156:
23:
255:Key:XQSZLXRXPGLHLH-UHFFFAOYSA-N
174:
150:
1:
277:non-alcoholic steatohepatitis
539:. You can help Knowledge by
482:. You can help Knowledge by
360:10.1016/j.biopha.2021.112324
319:10.1016/j.biopha.2023.115345
596:Experimental diabetes drugs
652:
518:
457:
140:Chemical and physical data
238:
218:
94:
80:
474:article relating to the
476:gastrointestinal system
38:, as no other articles
429:10.4093/dmj.2021.0056
533:hormonal preparation
626:Isopropyl compounds
268:is an experimental
77:
389:10.2337/db21-766-P
57:for suggestions.
47:to this page from
586:Receptor agonists
548:
547:
491:
490:
263:
262:
209:Interactive image
71:
70:
16:Chemical compound
643:
569:
562:
555:
527:
520:
512:
505:
498:
466:
459:
452:
451:
441:
431:
407:
401:
400:
383:(Supplement_1).
371:
365:
364:
362:
338:
332:
331:
321:
297:
273:receptor agonist
211:
191:
176:
170:
164:
158:
152:
132:
122:
121:
85:
78:
76:
66:
63:
52:
50:related articles
27:
19:
651:
650:
646:
645:
644:
642:
641:
640:
576:
575:
574:
573:
517:
516:
456:
455:
409:
408:
404:
373:
372:
368:
340:
339:
335:
299:
298:
294:
289:
281:type 2 diabetes
259:
256:
251:
246:
245:
234:
231:
226:
225:
214:
189:
179:
173:
167:
161:
155:
135:
118:
110:
107:
102:
101:
67:
61:
58:
48:
45:introduce links
28:
17:
12:
11:
5:
649:
647:
639:
638:
633:
628:
623:
618:
613:
608:
603:
598:
593:
588:
578:
577:
572:
571:
564:
557:
549:
546:
545:
528:
515:
514:
507:
500:
492:
489:
488:
467:
454:
453:
422:(2): 337–348.
402:
366:
333:
291:
290:
288:
285:
261:
260:
258:
257:
254:
252:
249:
241:
240:
239:
236:
235:
233:
232:
229:
221:
220:
219:
216:
215:
213:
212:
204:
202:
194:
193:
187:
181:
180:
177:
171:
165:
159:
153:
148:
142:
141:
137:
136:
134:
133:
125:
123:
112:
111:
109:
108:
105:
97:
96:
95:
92:
91:
87:
86:
69:
68:
55:Find link tool
31:
29:
22:
15:
13:
10:
9:
6:
4:
3:
2:
648:
637:
634:
632:
629:
627:
624:
622:
619:
617:
614:
612:
611:Phenol ethers
609:
607:
604:
602:
599:
597:
594:
592:
589:
587:
584:
583:
581:
570:
565:
563:
558:
556:
551:
550:
544:
542:
538:
535:article is a
534:
529:
526:
522:
513:
508:
506:
501:
499:
494:
493:
487:
485:
481:
477:
473:
468:
465:
461:
449:
445:
440:
435:
430:
425:
421:
417:
413:
406:
403:
398:
394:
390:
386:
382:
378:
370:
367:
361:
356:
352:
348:
344:
337:
334:
329:
325:
320:
315:
311:
307:
303:
296:
293:
286:
284:
282:
278:
274:
271:
267:
253:
248:
244:
237:
228:
224:
217:
210:
206:
205:
203:
200:
195:
188:
186:
182:
149:
147:
143:
138:
131:
127:
126:
124:
117:
113:
104:
100:
93:
88:
84:
79:
65:
62:December 2023
56:
51:
46:
42:
41:
37:
32:This article
30:
26:
21:
20:
616:Fluoroarenes
541:expanding it
530:
484:expanding it
469:
419:
415:
405:
380:
376:
369:
350:
346:
336:
309:
305:
295:
265:
264:
59:
33:
621:Oxadiazoles
606:Piperidines
601:Pyrimidines
192: g·mol
90:Identifiers
580:Categories
353:: 112324.
312:: 115345.
287:References
197:3D model (
185:Molar mass
99:IUPAC name
53:; try the
40:link to it
397:237883271
130:121304331
43:. Please
448:35052026
377:Diabetes
328:37657264
439:8987681
375:(HV)".
266:DA-1241
190:471.553
146:Formula
116:PubChem
75:DA-1241
446:
436:
395:
326:
270:GPR119
223:SMILES
36:orphan
34:is an
531:This
478:is a
470:This
393:S2CID
243:InChI
199:JSmol
537:stub
480:stub
472:drug
444:PMID
324:PMID
279:and
434:PMC
424:doi
385:doi
355:doi
351:144
314:doi
310:166
120:CID
582::
442:.
432:.
420:46
418:.
414:.
391:.
381:70
379:.
349:.
345:.
322:.
308:.
304:.
283:.
160:31
154:25
568:e
561:t
554:v
543:.
511:e
504:t
497:v
486:.
450:.
426::
399:.
387::
363:.
357::
330:.
316::
201:)
178:2
175:O
172:5
169:N
166:2
163:F
157:H
151:C
64:)
60:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
